Takeda Provides Update on TOURMALINE-AL1 Phase 3 Trial in AL Amyloidosis

40

CAMBRIDGE, Mass. & OSAKA, Japan–(BUSINESS WIRE)–Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE: TAK) today announced that the Phase 3 TOURMALINE-AL1 clinical trial in patients with relapsed or refractory systemic light-chain (AL) amyloidosis did not meet the first of two primary endpoints. Treatment with NINLAROTM (ixazomib) in combination with dexamethasone did not demonstrate a significant improvement in overall hematologic response compared to physician’s choice of standard of care….

 

 

http://www.businesswire.com/news/home/20190605005886/en/Takeda-Update-TOURMALINE-AL1-Phase-3-Trial-AL/?